


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.


Listing of Claims

1. (Currently Amended) A compound of formula (I):



wherein:

~~One~~ one of R^1 and R^2 is ~~selected from~~ a group (IA):



and the other R^1 or R^2 is selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, carbocyclyl, heterocyclyl, carbocycloxy and heterocycloxy; wherein this R^1 or R^2 ~~may be~~ is optionally substituted on carbon by one or more groups selected from R^5 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen ~~may be~~ is optionally substituted by C_{1-4} alkyl;

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl ~~may be~~ is optionally substituted on carbon by one or more groups selected from R^6 ;


one of R^3 and R^4 is hydrogen and the other is selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, carbocyclyl, heterocyclyl, carbocycloxy and heterocycloxy; wherein R^3 and R^4 ~~may be~~ are independently optionally substituted on carbon by one or more groups selected from R^7 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen ~~may be~~ is optionally substituted by C_{1-4} alkyl;

R^6 is selected from halo, carboxy and C_{1-4} alkyl;

R⁵ and **R⁷** are independently selected from halo, C₁₋₄alkyl, C₁₋₄alkoxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl, carbocycloxy, heterocycloxy and carbocyclidenyl; wherein **R⁵** and **R⁷** ~~may be~~ is independently optionally substituted on carbon by one or more **R⁸**; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen ~~may be~~ is optionally substituted by C₁₋₄alkyl; and **R⁸** is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and *N*-methyl-*N*-ethylamino; or a salt, solvate or pro-drug thereof.


2. (Currently Amended) A compound according to Claim 1 wherein one of **R¹** and **R²** is selected from a group (IA) and the other of ~~of **R¹** or~~ and **R²** is selected from C₁₋₄alkoxy; wherein this **R¹** or **R²** ~~may be~~ is optionally substituted on carbon by one or more groups selected from **R⁵**.
3. (Currently Amended) A ~~compounds~~ compound according to Claim 2 wherein Ring A in the group (IA) is substituted by carboxy and the C₁₋₄alkoxy group is substituted on carbon by one or more groups selected from **R⁵**.
4. (Original) A compound according to Claim 3 wherein **R⁵** is selected from carbocyclyl optionally substituted by one or more **R⁸**.
5. (Currently Amended) A compound according to ~~any one of the preceding claims~~ Claim 1 wherein one of **R³** and **R⁴** is hydrogen and the other is C₁₋₄alkyl.
6. (Original) A compound according to Claim 1 selected from:
 - 2-(2-Chlorobenzyloxy)-4-[*N*-(5-carboxythiazol-2-yl)carbamoyl]-6-methylquinoline;
 - 2-(2-Chlorobenzyloxy)-4-[*N*-(5-carboxythiazol-2-yl)carbamoyl]-quinoline;
 - 2-(2-Chlorobenzyloxy)-4-[*N*-(5-carboxypyrid-2-yl)carbamoyl]-6-methylquinoline;
 - 2-(2-Chlorobenzyloxy)-4-[*N*-(5-carboxypyrid-2-yl)carbamoyl]-quinoline;
 - 2-[*N*-(5-carboxypyrid-2-yl)carbamoyl]-4-(2-methylbenzyloxy)-quinoline; and
 - 2-(1-methylpropoxy)-4-[*N*-(5-carboxythiazol-2-yl)carbamoyl]-quinoline;or a salt, solvate or pro-drug thereof.

7. (Original) A pharmaceutical composition comprising a compound according to any one of Claims 1 to 6, or a salt, pro-drug or solvate thereof, together with a pharmaceutically acceptable diluent or carrier.
8. (Currently Amended) A method of treating a disease mediated through glucokinase, comprising administering a compound according to any one of Claims 1 to 6 for use in the preparation of a medicament for treatment of a disease mediated through GLK.
9. (Currently Amended) A process for preparing a compound according to Claim 1 of formula (I):



wherein:

one of R¹ and R² is a group (IA):



and the other R¹ or R² is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein this R¹ or R² is optionally substituted on carbon by one or more groups selected from R⁵; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl;

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl is optionally substituted on carbon by one or more groups selected from R⁶;

one of R³ and R⁴ is hydrogen and the other is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein

R³ and R⁴ are independently optionally substituted on carbon by one or more groups selected from R⁷; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl;


R⁶ is selected from halo, carboxy and C₁₋₄alkyl;

R⁵ and R⁷ are independently selected from halo, C₁₋₄alkyl, C₁₋₄alkoxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl, carbocycloxy, heterocycloxy and carbocyclidenyl; wherein R⁵ and R⁷ is independently optionally substituted on carbon by one or more R⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl; and


R⁸ is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino,

or a salt, solvate or pro-drug thereof, which process (~~wherein variable groups are, unless otherwise specified, as defined in Claim 1~~) comprises:

Process 1): reacting an acid of formula (IIa) or (IIb):




or an activated derivative thereof; with a compound of formula (III)




or

Process 2) for compounds of formula (I) wherein R⁶ is carboxy; deprotecting a compound of formula (IIIa) or (IIIb):



(IIIa)



(IIIb)

wherein $R^x C(O)O-$ is an ester group;

and optionally further comprises thereafter if necessary or desirable:


i) converting a compound of the formula (I) into another compound of the formula (I);

and/or

ii) removing any protecting groups; ~~and/or~~

iii) forming a salt, solvate or pro-drug thereof; or a combination thereof.

10. (Currently Amended) A compound of formula (IIIa) or a compound of formula (IIIb);
~~as defined in Claim 9~~



(IIIa)

(IIIb)

wherein:

$R^x C(O)O-$ is an ester group;

R^1 or R^2 is selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, carbocyclyl, heterocyclyl,

carbocycloxy and heterocycloxy; wherein this R^1 or R^2 is optionally substituted

on carbon by one or more groups selected from R⁵; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl;

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl is optionally substituted on carbon by one or more groups selected from R⁶;

one of R³ and R⁴ is hydrogen and the other is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, carbocyclyl, heterocyclyl, carbocycloxy and heterocycloxy; wherein R³ and R⁴ are independently optionally substituted on carbon by one or more groups selected from R⁷; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl;

R⁶ is selected from halo, carboxy and C₁₋₄alkyl;

R⁵ and R⁷ are independently selected from halo, C₁₋₄alkyl, C₁₋₄alkoxy, N-(C₁₋₄alkyl)amino, N,N-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl, carbocycloxy, heterocycloxy and carbocyclidenyl; wherein R⁵ and R⁷ is independently optionally substituted on carbon by one or more R⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl; and

R⁸ is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N-methyl-N-ethylamino.